Viromed Medical AG has completed its transition from bearer shares to registered shares following a resolution approved by shareholders at the Annual General Meeting on July 29, 2025. The conversion, which became effective after entry in the commercial register on August 8, 2025, marks a structural change in how the medical technology company manages its shareholder relationships and corporate governance.
The technical conversion process occurred on January 16, 2026, when all 21,250,000 bearer shares previously held under ISIN DE000A3MQR65 were deregistered by custodian banks and Clearstream Banking AG. Shareholders received one new registered share for each previous bearer share, with each share representing €1.00 of share capital under the new ISIN DE000A40VZN7. The company has excluded the right to individual certification, instead maintaining the share capital in a global certificate deposited with Clearstream Banking AG.
Trading of the new registered shares commenced on January 15, 2026, one day before the technical conversion, while the previous bearer shares traded for the final time on January 14, 2026. This transition maintains shareholder rights unchanged, with no impact on ownership percentages or associated rights. The company emphasizes that shareholders retain full ability to sell their shares, as registered share transfers do not require company approval.
This corporate action represents more than a technical change in share structure. The move to registered shares enables Viromed Medical AG to maintain direct communication channels with its shareholders, potentially improving corporate transparency and governance. As a publicly traded company since October 2022, this transition aligns with evolving standards for shareholder engagement in the medical technology sector.
Viromed Medical AG, which operates through its subsidiary Viromed Medical GmbH, focuses on distributing innovative cold plasma technology for medical applications. The company serves customers across the DACH region and beyond, pursuing growth through advancing cold plasma applications in medicine. This share structure change supports the company's long-term strategy while providing shareholders with enhanced visibility into ownership structure.
The conversion's importance extends beyond administrative changes to fundamental shifts in how companies interact with investors. Registered shares provide companies with clearer insight into their shareholder base, potentially enabling more targeted communication and engagement strategies. For shareholders, this structure offers increased transparency regarding ownership rights and corporate actions.
As medical technology companies navigate increasingly complex regulatory environments and investor expectations, structural changes like Viromed's share conversion demonstrate evolving approaches to corporate governance. The transition maintains trading liquidity while potentially strengthening the relationship between the company and its investors, an important consideration for growth-oriented firms in competitive sectors.
Additional information about the company is available at https://www.viromed-medical-ag.de. The original announcement detailing this corporate action was published through standard financial communication channels, providing investors with comprehensive information about the transition process and its implications for share ownership and trading.
